REVVITY INC
RVTYNYSETrading Snapshot
- Day Range
- $151.06 โ $153.99
- 52-Week Range
- $81.22 โ $152.26
- Volume
- $1.71B
- Avg Volume
- $1.72B
- Shares Outstanding
- 111.6M
- Next Earnings
- Nov 30, 2026
Fundamentals Snapshot
- Annual Revenue
- $2.86B
- Last Q Revenue
- $730M
- P/E Ratio
- 70.3
- P/S Ratio
- 5.7x
- EPS (TTM)
- $2.10
- Dividend Yield
- 0.19%
- Dilution (1yr)
- โ6.9%
Why Investors Own RVTY
- โHigh-growth profile โ revenue up +8.9% YoY with expanding US Equity exposure.
- โHealthy economics โ 49% gross margin and 18% free-cash-flow margin.
- โNew products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
REVVITY INC
RVTYAbout REVVITY INC
Revvity, Inc., founded in 1937 and based in Waltham, Massachusetts, is a global enterprise that develops and delivers a wide array of products, services, and solutions. The company, which changed its name from PerkinElmer, Inc. in April 2023, caters to the diagnostics, life sciences, and applied services sectors worldwide. Its Discovery & Analytical Solutions division provides advanced instrumentation, reagents, informatics, software, subscriptions, and sophisticated detection and imaging technologies. These resources are designed to enable scientists to achieve significant breakthroughs in life sciences research. This segment also offers contract research and specialized laboratory services. Furthermore, it supplies analytical tools and services for assessing environmental health, including air, water, and soil, and delivers solutions to agricultural and food producers. It also serves the industrial market with analytical instrumentation for sectors such as chemical, semiconductor, electronics, energy, lubricants, petrochemicals, and polymers. The Diagnostics segment is dedicated to early detection, offering instruments, reagents, assay platforms, and software for identifying genetic disorders in pregnant individuals and young children, alongside infectious disease testing. Its products facilitate the screening of genetic abnormalities, disorders, and diseases like Down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This division also innovates technologies that support genomic workflows, leveraging protein-coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. Revvity serves a diverse clientele, including pharmaceutical and biotechnology firms, laboratories, academic and research institutions, public health authorities, private healthcare organizations, medical professionals, and government bodies.
Otter Score Breakdown
How it's scoredFive components, each rated 1โ5โ and equally weighted (20%), averaged to a 0โ100 score:๐ Quality โ gross margin๐ Growth โ revenue YoYโ๏ธ Valuation โ P/S ratioโก Momentum โ 30-day price change๐ง Dilution โ 1-yr share issuance (buybacks score higher)Analyst Price Target
โLatest News & Updates
Here's Why You Should Retain Revvity Stock in Your Portfolio for Now
RVTY's diagnostics growth, AI-driven demand and life sciences expansion support its outlook, though China and margin pressures pose near-term challenges.

RVTY Launches New Kit in Europe for Newborn Type 1 Diabetes Detection
Revvity launches a CE-IVDR-certified automated T1D screening kit for children, expanding its GSP platform from newborn screening into early childhood.

Revvity Launches IVDR-Certified Solution for Early Detection of Type 1 Diabetes
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) today announced the launch of the GSPยฎ T1D 3plex kit, a fully automated, CE-IVDR-certified, multiplex autoantibody (AAb) detection solution to enable population

Reviewing Codexis (NASDAQ:CDXS) & Revvity (NYSE:RVTY)
Revvity (NYSE: RVTY - Get Free Report) and Codexis (NASDAQ: CDXS - Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuat

Revvity Inc. $RVTY Shares Acquired by State Street Corp
State Street Corp boosted its stake in Revvity Inc. (NYSE: RVTY) by 0.8% during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 4,342,739 shares

Critical Survey: Revvity (NYSE:RVTY) vs. Cytek Biosciences (NASDAQ:CTKB)
Revvity (NYSE: RVTY - Get Free Report) and Cytek Biosciences (NASDAQ: CTKB - Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of